Publication | Open Access

Identification of time point to best define ‘sub-optimal response’ following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data

Ocular DiseaseReal-life DataTime PointOphthalmologyDiabetesEye HealthGlaucomaDiabetic Macular EdemaMedicine